Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

SBC Medical Group Holdings (SBC) Shares Outstanding (Weighted Average) (2023 - 2025)

SBC Medical Group Holdings (SBC) has disclosed Shares Outstanding (Weighted Average) for 3 consecutive years, with $102.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Weighted Average) rose 7.94% year-over-year to $102.6 million, compared with a TTM value of $102.6 million through Sep 2025, up 7.94%, and an annual FY2024 reading of $96.6 million, up 2.51% over the prior year.
  • Shares Outstanding (Weighted Average) was $102.6 million for Q3 2025 at SBC Medical Group Holdings, down from $103.4 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $103.4 million in Q2 2025 and bottomed at $2.9 million in Q1 2023.
  • Average Shares Outstanding (Weighted Average) over 3 years is $80.8 million, with a median of $94.2 million recorded in 2023.
  • Peak annual rise in Shares Outstanding (Weighted Average) hit 3176.26% in 2024, while the deepest fall reached 0.96% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $94.2 million in 2023, then rose by 2.51% to $96.6 million in 2024, then increased by 6.3% to $102.6 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for SBC at $102.6 million in Q3 2025, $103.4 million in Q2 2025, and $103.3 million in Q1 2025.